期刊文献+

非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义

Levels and clinical significance of PA28γand miR-7-5p in tumor tissues of patients with non-small cell lung cancer
下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)患者癌组织中蛋白酶体激活因子PA28γ及微小RNA-7-5p(miR-7-5p)表达水平与术后生存的相关性。方法回顾性分析2018年3月—2020年5月间接受手术治疗的82例NSCLC患者临床资料,使用免疫组化法和qPCR法测定其癌组织及癌旁组织标本中PA28γ、miR-7-5p表达情况并分析其与NSCLC患者病理特征的关系。术后随访14~42个月,观察患者生存情况,绘制ROC曲线分析癌组织中PA28γ、miR-7-5p表达对NSCLC患者预后的预测效果。结果免疫组化法检测NSCLC组织中PA28γ表达水平显著高于癌旁组织,qPCR法测定miR-7-5p相对表达量明显低于癌旁组织(P<0.05);NSCLC癌组织中PA28γ表达与miR-7-5p呈负相关性(r=-0.557,P<0.001);PA28γ表达与肿瘤分化程度、TNM分期、浸润深度及远处转移相关(P<0.05);miR-7-5p表达与肿瘤病理类型、分化程度、TNM分期、浸润深度及远处转移相关(P<0.05)。ROC曲线分析显示PA28γ表达预测生存率的AUC为0.696(95%CI:0.555-0.837),miR-7-5p表达的AUC为0.853(95%CI:0.735-0.971)。结论NSCLC组织中的PA28γ及miR-7-5p均存在异常表达情况,且均与癌细胞分化程度、TNM分期、浸润深度和远处转移等病理特征密切相关,推测其共同参与了NSCLC的发生及进展过程,可作为NSCLC早期诊断和靶向治疗的肿瘤标记物。 Objective The objective of this study was to investigate the correlation between the expression of proteasome activating factor PA28γand microRNA-7-5p(miR-7-5p)and postoperative survival in cancer tissues of patients with non-small cell lung cancer(NSCLC).Methods The clinical data of 82 NSCLC patients who underwent surgical treatment from March 2018 to May 2020 were retrospectively analyzed,and immunohistochemistry and qPCR were used to detect the expression of PA28γand miR-7-5p in cancer tissue and adjacent tissue samples.Their correlation between PA28γand miR-7-5P and pathological characteristics of NSCLC patients was analyzed.Postoperative follow-up was conducted for 14 to 42 months to observe the patient′s survival and draw a ROC curve to analyze the predictive effect of PA28γand miR-7-5p expression in cancer tissues on the prognosis of patients with NSCLC.Results The expression of PA28γin NSCLC cancer tissues was significantly higher than that in adjacent tissues as determined by immunohistochemistry.The expression of miR-7-5p was significantly lower than that in adjacent tissues as determined by qPCR(P<0.05).PA28γexpression in NSCLC cancer tissues was significantly different from that in adjacent tissues,and negatively correlated with miR-7-5p(r=-0.557,P<0.001).The expression of PA28γwas correlated with tumor differentiation,TNM stage,depth of invasion and distant metastasis(P<0.05);the expression of miR-7-5p was correlated with tumor pathological type,degree of differentiation,TNM staging,depth of invasion and distant metastasis(P<0.05).The ROC curve analysis showed that the AUC of PA28γexpression in predicting survival was 0.696(95%CI:0.555-0.837),and the AUC of miR-7-5p expression was 0.853(95%CI:0.735-0.971).Conclusion Both PA28γand miR-7-5p are abnormally expressed in NSCLC tissues,and are closely related to the pathological characteristics such as cancer cell differentiation degree,TNM stage,depth of invasion,and distant metastasis.It is speculated that they are both involved in the occurrence and development of NSCLC,which can be used as a tumor marker for early diagnosis and targeted therapy of NSCLC.
作者 苗玲 赵之寒 王敏 MIAO Ling;ZHAO Zhihan;WANG Min(Thoracic Surgery,Handan Central Hospital,Handan 056000,China)
出处 《实用肿瘤学杂志》 CAS 2023年第4期344-350,共7页 Practical Oncology Journal
基金 河北医学科学研究课题(编号:20200194)。
关键词 非小细胞肺癌 蛋白酶体激活因子PA28γ miR-7-5p 临床意义 预后 Non-small cell lung cancer Proteasome activator PA28γ miR-7-5p Clinical significance Prognosis
  • 相关文献

参考文献9

二级参考文献34

  • 1Froes Brandao D,Strasser-Weippl K,Goss PE.Prolactin and breast cancer:The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients:A review[J].Cancer,2016,122(2):184-188.
  • 2De Mattos-Arruda L,Bottai G,Nuciforo PG,et al.MicroRNA-21links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients[J].Oncotarget,2015,6(35):37269-37280.
  • 3Wang J,Yang M,Li Y,et al.The Role of MicroRNAs in the Chemoresistance of Breast Cancer[J].Drug Dev Res,2015,76(7):368-374.
  • 4Le Blanc VC,Morin P.Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients[J].J Clin Med,2015,4(8):1612-1630.
  • 5Bertoli G,Cava C,Castiglioni I.MicroRNAs:new biomarkers for diagnosis,prognosis,therapy prediction and therapeutic tools for breast cancer[J].Theranostics,2015,5(10):1122.
  • 6Lee KM,Choi EJ,Kim IA.microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling[J].Radiother Oncol,2011,101(1):171-176.
  • 7Li Q,Zhu F,Chen P.miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting Hox B3 in breast cancer[J].Biochem Biophys Res Commun,2012,424(1):28-33.
  • 8Huynh FC,Jones FE.MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance[J].PLo S One,2014,9(12):e114419.
  • 9Glover AR,Zhao JT,Gill AJ,et al.microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma[J].Oncotarget,2015,6(34):36675-36688.
  • 10Hao Z,Yang J,Wang C,et al.MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer[J].Int J Clin Exp Med,2015,8(1):480-487.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部